Gordon HOLT
Chief Science Officer, NorthShore Bio, USA

Gordon is a founder and the Chief Science Officer of NorthShore Bio, a Seattle USA biotech company developing chip-based arrays of electrically tunable nanopores.  The lead applications for this revolutionary technology are in the genome-scale sequencing of DNA and RNA.  Gordon earned a BA in Chemistry from Washington University in St. Louis, and a PhD in biochemistry from Johns Hopkins University School of Medicine. He has carried out academic research on parasitic and viral infection, as well as identified the causes of rare genetic diseases at the National Institutes of Health.  He also directed science development at Oxford GlycoSciences in proteomics, and developed a small molecule therapeutic currently in use to treat neurodegenerative genetic diseases.  In addition, he directed biotechnology business development efforts at Intel focusing on chip-based label-free electrical detection sensors. Gordon also has served as an expert biomarker panelist for FDA, published widely, and has patents on a variety of technologies ranging from chip-based sensors to small molecule therapeutics.